A new VC firm founded in 2017 and based in the Mid-Atlantic region of the USA is actively looking for post-seed investment opportunities in which the firm’s partners can contribute significant value. The size of investment will vary on a case-by-case basis. Currently, the firm will only consider companies that are based in the USA.

The firm is most interested in medical devices and healthcare IT/digital health/AI in healthcare start-up companies with a unique, high-growth potential product or technology. The firm is highly interested in surgical devices that can dramatically improve outcomes in healthcare systems. Ideally, these companies should have broad IP protection and have existing first paying customers. The firm will not consider opportunities in the therapeutics sector.

The firm will evaluate investment opportunities based on a proprietary scoring model, which includes the company’s market size/niche, growth potential, management team, exit potential, etc. The firm will expect to see management teams with strong expertise in their company’s relevant sectors, as well as a strong business model. The firm will always take a board seat and one of the firm’s general partners will act as an entrepreneur-in-residence (EIR), taking an active role by serving as an advisor and providing project-specific expertise. The firm can act as the lead investor or co-invest with other funds.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A Boston-based venture capital firm that raised a fund in 2017 makes early stage equity investments of about $10-15 million, and can either lead investments or co-invest. The firm will consider investment opportunities worldwide.

The firm invests primarily in therapeutic opportunities. The firm is open to investing in any indication area; areas of high interest include precision medicine approaches, autoimmune diseases, oncology, neurology (particularly diseases with genetically defined populations), dermatology and ophthalmology. Generally, the firm is less interested in broad patient populations such as diabetes, Alzheimer’s disease, or cardiovascular disease. The firm generally invests from late preclinical (1-2 years pre-IND) through to Phase II, and prefers to invest in assets with good animal model and/or genetic evidence to support efficacy a3

nd target validation.

The firm only invests in privately held companies. The firm prefers to work with management teams that have had prior startup successes. The firm is an active investor and the partners have deep experience in company building, and is therefore interested in providing support on strategy, BD, recruiting and other areas of active management in addition to providing capital.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A large not-for-profit healthcare system serves over 2 million people each year has created a strategic investment arm, which launched in 2016 with an inaugural $150M allocation dedicated to investing in innovative companies that fit the healthcare system’s key strategic priorities: safety & quality, analytics, clinical innovations, and technology. The strategic arm focuses on Series A to B funding in innovative companies and will also invest in funds that share the same strategic vision. The firm’s investment sizes typically range from $1-2 million and the firm invests globally. In addition, the firm supports the growth of early-stage companies through an accelerator program.

The firm is focused on personalized health technologies and will consider innovations in medical devices, diagnostics, and healthcare IT/digital health. However, the firm will not invest in therapeutics or Class III (PMA) devices/products. Examples of current investments include a diagnostic company that enables health systems to deliver patient-specific diagnostic and treatment options based on the individual’s DNA, a company developing an automated online platform for patients to better manage their healthcare bills and payments, etc. All technologies must have passed conceptual stage of development and have a valid proof-of-concept.

The firm seek to work with companies that have mitigated technical risk and have achieved initial market validation for their products and technology. The firm will also evaluate companies on the basis of strategic and market fit from a health systems perspective. The firm is a strategic investor and invests in companies in which it intends to use the company’s products or services. The firm has led investment rounds, but generally co-invest with other syndicates. The firm does not always require a board seat in its portfolio companies. The firm’s accelerator program will consider earlier stage companies, including less technical, market and management team development.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A major health insurance firm has formed a collaborative corporate investment vehicle that is based in the US Midwest. The firm is looking to make investments ranging from $5 – $15 million over the lifetime of the investment in stages ranging anywhere from seed to buyout. The firm looks to invest in companies of strategic interest to the payer while also seeking strong financial returns. The firm is actively reviewing new opportunities and will consider companies located around the globe.

The firm is looking to invest in sectors of Healthcare IT, Services, and Diagnostics and to a lesser extent wearable devices. The firm is most interested in companies that are have reached or are very near FDA approval and are targeting large market indications.

The firm is looking for companies with experienced management teams and prefer working with complete teams although they also have experience and are willing to work with incomplete management teams as well. The firm is looking for privately held companies and is open to either lead or co-invest in rounds. The firm generally looks to take a board seat following investment.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

An investor group based out of New York, USA with financial backing from China in looking at US-based opportunities that they believe will translate well to the Chinese market. These opportunities do not need to already have traction in China since the firm hopes to be a Chinese partner to help them access and succeed in these markets in addition to being an investor. The firm expects to make 20-50 investments this year and is prioritizing investments in the $10-50 million USD range, but is also willing to look at earlier stage opportunities.

The firm is interested in medical devices. Specifically, medical devices related to senior care, health planning, data collection, data analysis and management, 24/7 patient monitoring systems, and devices that can help facilitate conversations between patients and caregivers. Companies they’ve worked with and still have interest for include: laser treatment devices for arthritis, devices for rehabilitation, and devices for surgery. The firm is generally less interested in pure healthcare IT. For device companies, the firm prefers that they already have FDA approval, but are willing to look at companies who are close to completing FDA pivotal trials as well.

The firm prefers companies that are ideally already revenue generating, but they are also willing to look at companies that are near revenue generation. The firm wants to work with companies who are interested in accessing the Chinese market and are willing to form a joint venture with the firm in China.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A diversified business based in Japan has opened US corporate venture offices in Massachussets and California. The corporate venture fund has an evergreen structure looking to allocate between $1-$3 million per deal initially and up to $5 million over the life of the investment. The firm seeks to invest in approximately 2-4 companies over the next 12 months and are open to investing in companies across the globe.

Sectors of interest include: pharmaceuticals, medical device and digital health. Therapeutic and product areas of interest include: Pain, critical care, cardiovascular disease, musculoskeletal disease, kidney disease, patient monitoring technologies, bioprocessing technologies, digital therapeutics. The firm is open to all stages of investment, with a general preference toward companies with at least some early clinical data.

The firm invests in private companies and is willing to work with all types of management teams including incomplete teams. They generally request at least an observer seat following investment.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

Yuanta Asia Investment is an investment firm based in Taiwan. The firm is the subsidiary of Yuanta Securities, a Taiwanese securities house with approximately USD 6.8 billion AUM and subsidiary of Yuanta Financial Holdings. The firm engages in M&A, underwriting, as well as direct investments. The firm is interested in the life sciences and will target new investments from a new USD 100 million fund. The firm can sometimes leverage different funds to invest. The fund’s target investment size is USD 3-5 million per company in average, USD 5-15M for pre-IPO round and USD 1-1.5 million for early stage companies. Capital allocation per company will not exceed 10% of the fund. The firm seeks companies in Asia-Pacific, including the US and Japan. The firm is actively seeking new investment opportunities.

In the life sciences, the firm is interested in therapeutics, medical devices, and diagnostics. For therapeutics, the firm will consider a broad range of modalities including small molecules and biologics with an emphasis on immunotherapy or other breakthrough technology in CNS related disease. The firm is opportunistic in terms of indications. For companies in Asia, the firm is agnostic to the phase of development. For overseas deals, the firm is currently looking for preclinical to phase 2 assets. The firm prefers candidates with in-human data and are conducting clinical trials in the US, while this is not a requirement.

For devices, the firm considers minimally invasive class III devices in the cardiovascular and cancer space that have prototype and have obtained proof-of concept. For diagnostics, the firm is interested in genomics and big data analytics. Recently there is an interest in the cosmetics and supplements area, and the firm is seeking acquisition opportunities to commercialize products through distribution channels within its network. The firm is also looking for the target in pre-IPO round of placement in NASDAQ or other market.

The firm only invests in private companies and looks to hold less than 15 percent of total shares of the company.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com